Glofitamab (RO7082859) 是一种与 T 细胞结合的双特异性抗体，具有新颖的 2:1 结构，B 细胞上的CD20 为二价，T 细胞上的 CD3 为一价。Glofitamab 与恶性细胞上的 CD20 结合后，可导致 T 细胞活化、增殖和肿瘤细胞杀伤。Glofitamab 可诱导复发或难治性 B 细胞淋巴瘤的持久完全缓解。
| 生物活性 | Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency forCD20on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding toCD20on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma[1][2]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
